Büttner, Thomas
Maerevoet, Marielena K. E.
Giordano, Frank A.
Veldwijk, Marlon R.
Herskind, Carsten
Ruder, Arne Mathias
Funding for this research was provided by:
Rheinische Friedrich-Wilhelms-Universität Bonn
Article History
Received: 28 May 2023
Accepted: 21 December 2023
First Online: 30 January 2024
Declarations
:
: Not applicable.
: Not applicable.
: A.M.R. and F.A.G. are co-inventors in the patents pending EP4119191A1 and WO2023285170A1, “Xenon gas for use in the treatment of gliomas”. A.M.R. has received or receives personal fees and/or travel expenses from Carl Zeiss Meditec AG. F.A.G. has received or receives research grants, personal fees and/or travel expenses from Carl Zeiss Meditec AG, personal fees from Roche Pharma AG and Medac, grants and personal fees from AstraZeneca, Bristol-Myers Squibb, Cureteq AG, Elekta AB, FoMF GmbH, Guerbet SA, MSD Sharp and Dohme GmbH and Opasca GmbH, stocks, grants and personal fees from TME Pharma AG (formerly Noxxon Pharma AG), compensation for advisory boards from the Federal Joint Committee (G-BA) of the Federal Republic of Germany and of the German Cancer Aid and non-financial support from Oncare GmbH and Opasca GmbH. The remaining authors declare that they have no competing interests.